Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $20.34, for a total value of $135,606.78. Following the completion of the transaction, the chief operating officer now directly owns 303,309 shares of the company’s stock, valued at approximately $6,169,305.06. This represents a 2.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Anish Patel also recently made the following trade(s):

• On Wednesday, May 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.39, for a total transaction of $122,606.13.
• On Monday, April 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.04, for a total transaction of $120,272.68.

Enliven Therapeutics Stock Down 9.7%

Shares of ELVN opened at $19.60 on Thursday. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03. The stock has a fifty day simple moving average of $18.14 and a two-hundred day simple moving average of $20.72. The company has a market capitalization of $961.75 million, a PE ratio of -10.32 and a beta of 0.79.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06). As a group, equities analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ELVN. Jones Trading lowered their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating on the stock in a research report on Friday, May 16th. HC Wainwright boosted their target price on Enliven Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, May 15th.

Institutional Trading of Enliven Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its position in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after buying an additional 1,114 shares during the period. GAMMA Investing LLC increased its stake in Enliven Therapeutics by 3,058.1% during the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock worth $53,000 after acquiring an additional 2,630 shares during the last quarter. Quantbot Technologies LP purchased a new stake in Enliven Therapeutics in the first quarter valued at $60,000. KLP Kapitalforvaltning AS purchased a new stake in Enliven Therapeutics in the fourth quarter valued at $97,000. Finally, BNP Paribas Financial Markets acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at $112,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.